Semaglutide's Hidden Challenge: Many Patients Don't Achieve Optimal Results

Semaglutide has emerged as a leading therapeutic agent for managing obesity and type 2 diabetes, demonstrating robust efficacy in improving metabolic health and reducing associated cardiovascular and renal risks. Despite its widespread adoption and proven benefits, there is currently limited comprehensive data on the proportion of patients who experience suboptimal therapeutic responses or discontinue treatment due to adverse events. This knowledge gap is crucial for understanding the real-world effectiveness of this important medication.

The meta-analysis revealed significant insights into semaglutide's real-world effectiveness. Across all included trials, 33.4% of participants did not achieve a ≥5% total body weight reduction, while a larger proportion, 65.1%, failed to achieve a ≥10% total body weight reduction. Stratified analyses highlighted a notable difference based on diabetes status: Among individuals with type 2 diabetes mellitus (T2DM), an alarming 79.8% did not achieve ≥10% weight loss, a stark contrast to the 30.1% observed in participants without T2DM. This indicates that patients with T2DM are significantly more prone to suboptimal weight loss outcomes when treated with semaglutide. The study also noted that a substantial subset of patients experienced suboptimal glycemic improvements or discontinued therapy, though specific percentages for these outcomes were not detailed in the abstract.